Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Homes 4 Rent Class A (AMH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

American Homes 4 Rent Class ATrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

American Homes 4 Rent Class A vs Regeneron Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.43 (market cap $11.97B), while Regeneron Pharmaceuticals Inc trades at $658.21 (market cap $69.67B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.8× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.97%). Which is the better fit depends on your goals.

AMHREGN
Market Cap
$11.97B$69.67B
Sector
Real EstateHealth
52-Week High
$36.74$812.27
52-Week Low
$27.38$542.52
Enterprise Value
$17.05B$63.62B
Dividend Yield
3.97%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Homes 4 Rent Class A

AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.

Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $664.52, down 0.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong fundamentals with a P/E of 16.22, net income margin of 29.65%, and consistent earnings beats. Recent FDA acceptance for cemdisiran review and inclusion in a manufacturing facility pilot program highlight positive developments. Cash flow improved in 2025 with net cash flow of $634.70 million.

Outlook remains positive with a consensus price target of $764.50, implying 15% upside, supported by 69% analyst buy ratings. Risks include regulatory hurdles, competitive pressures, and dependence on key drug performance. The stock presents a compelling opportunity for growth investors given its valuation and pipeline progress, though near-term volatility may persist around earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Homes 4 Rent Class A

American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas

Read more on AMH

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN